Jun. 15 at 6:15 PM
$AIFF Why Firefly Neuroscience Could Be a Compelling Investment
Firefly Neuroscience combines AI, neuroscience, and a proprietary data advantage that few companies can replicate. It has assembled the world's largest known standardized EEG/ERP brain database (200,000+ scans), creating a powerful foundation for AI-driven biomarker discovery and clinical decision support.
The company already has FDA-cleared technology, is expanding commercial scan volumes, has announced a U.S. defense brain-health partnership, and recently identified a novel PTSD electrophysiological biomarker using its AI platform.
If Firefly demonstrates that its technology can objectively measure and track brain-state changes over time—particularly through Alzheimer's and pharmaceutical research—it could become an essential platform for diagnosis, drug development, and treatment monitoring across multiple neurological disorders.
The opportunity is high risk, but the potential upside is significant:
